A Study of DPC 817 in HIV-Infected Males

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will consist of two parts. Patients in Part A will receive a single dose of DPC 817 on two separate occasions and a placebo (a solution or tablet without the drug) on one occasion. Patients in Part B will receive two separate doses of DPC 817. Patients will be admitted to the clinical study unit the day before dosing (Day -1) and remain there for at least 48 hours after taking the study drug. Patients will return to the clinical study unit on Day 8 and Day 28 following the dose in the last treatment period. During the study there will be medical and medication histories taken, physical examinations, vital sign measurements, and routine clinical laboratory tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV Phase I

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DPC 817

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients may be eligible for this study if they:

* Are HIV positive
* Are male and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age
* Are female and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age and are not able to have children (females may participate in Part B only)
* Have no clinically significant findings on physical examination or clinical laboratory evaluations
* Have a CD4-lymphocyte count of 50 or more cells/mm3
* Are able and willing to comply with the requirements of this study

Exclusion Criteria

Patients will not be eligible for this study if they:

* Have an opportunistic infection characteristic of AIDS
* Are receiving any approved or experimental HIV drugs. Any previous anti-HIV treatment must be stopped at least 4 weeks before the first dose of study medication
* Are pregnant or breast-feeding
* Are enrolled in other experimental drug studies or have recieved other experimental drugs within 30 days before the first dose of study drug
* Have any disease that causes a problem with absorption of drugs
* Have active hepatitis
* Have a history of pancreatitis or peripheral neuropathy
* Have received radiation therapy or chemotherapy within 30 days before the first dose of study drug
* Have received treatment with drugs that affect the immune system within 30 days before the first dose of study drug or have received an HIV immunotherapeutic vaccine
* Have taken prescription or over-the-counter products within 14 days of the first dose of study drug unless approved by the doctor
* Are unable to comply with the dosing schedule and study procedures

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of North Carolina Hospitals

Chapel Hill, North Carolina, United States

Site Status

3ClincalResearch Center

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DPC 817-201

Identifier Type: -

Identifier Source: org_study_id

NCT00023270